Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Lenzilumab Biosimilar - Anti-CSF2 mAb - Research Grade |
---|---|
Source | CAS 1229575-09-0 |
Species | Homo sapiens |
Expression system | Mammalian cells |
Purity | >85% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Applications | ELISA,WB |
Aliases /Synonyms | Lenzilumab,KB-003,CSF2,anti-CSF2 |
Reference | PX-TA1360 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1-kappa |
Clonality | Monoclonal Antibody |
Lenzilumab is investigated for the treatment of Chronic Myelomonocytic Leukemia (CMML).
Immobilized CSF2 / GM-CSF (in Mammalian), C-His, recombinant protein (cat. No. PX-P5667) at 0.5µg/mL (100µL/well) can bind Lenzilumab Biosimilar - Anti-CSF2 mAb (cat. No. PX-TA1360) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 33.07M.
Lenzilumab Biosimilar - Anti-CSF2 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Related products
Reviews
Il n’y a pas encore d’avis.